A. Mocroft

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chronic Kidney Disease and Exposure to ART in a large cohort with Long-term Follow-up: The EuroSIDA study

A. Mocroft, O. Kirk, J. Gatell, 2010 .

Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study

A. Mocroft, C. Sabin, A. Phillips, 2016, Antiviral therapy.

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.

A. Mocroft, C. Katlama, C. Toro, 2008, The Journal of infectious diseases.

Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.

A. Mocroft, F. Ceccherini‐Silberstein, B. Clotet, 2007, The Journal of infectious diseases.

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia

A. Mocroft, F. Antunes, C. Katlama, 2006, AIDS.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

A. Mocroft, C. Katlama, P. Reiss, 2019, PloS one.

A. Mocroft, M. Egger, M. Prins, 2011, Blood.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2017, PloS one.

Incidence of abacavir hypersensitivity reactions in EuroSIDA

A. Mocroft, O. Kirk, J. van Lunzen, 2008, Antiviral therapy.

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, Open forum infectious diseases.

Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.

A. Mocroft, V. Martel-Laferrière, M. Battegay, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

A. Mocroft, C. Sabin, P. Reiss, 2016, AIDS.

European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2016, HIV medicine.

Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

A. Mocroft, O. Kirk, N. Chentsova, 2009, AIDS.

Deteriorating renal function and clinical outcomes in HIV-positive persons

A. Mocroft, O. Kirk, J. Gatell, 2014, AIDS.

Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults

A. Mocroft, A. Szymczak, M. Bickel, 2012, PloS one.

Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

A. Mocroft, O. Kirk, P. Reiss, 2014, AIDS.

Advanced chronic kidney disease, end‐stage renal disease and renal death among HIV‐positive individuals in Europe

A. Mocroft, O. Kirk, J. Lundgren, 2013, HIV medicine.

Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting.

A. Mocroft, M. Johnson, J. Lundgren, 2020, Journal of acquired immune deficiency syndromes.

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.

C. Leen, A. Mocroft, M. Laguno, 2020, AIDS.

Clinical outcomes in persons coinfected with HIV and HCV: Impact of HCV treatment

R. Haubrich, A. Mocroft, J. Lundgren, 2019, Clinical Infectious Diseases.

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

R. Haubrich, A. Mocroft, J. Lundgren, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cessation of cigarette smoking and the impact on cancer incidence in HIV-positive persons : The D : A : D Study

A. Mocroft, R. Weber, C. Sabin, 2018 .

Continuation of hormone replacement therapy after hysterectomy

A. Mocroft, J. Studd, C. Domoney, 2003, Climacteric : the journal of the International Menopause Society.

Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV

A. Mocroft, J. Vestbo, S. Nielsen, 2021, Frontiers in Immunology.

Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe.

A. Mocroft, O. Kirk, N. Chentsova, 2014, The Journal of infection.

Use of risk equations for predicting disease progression in HIV infection.

A. Mocroft, J. Lundgren, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients

A. Mocroft, J. Lundgren, J. Reekie, 2022, Cancers.

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients

A. Mocroft, J. Lundgren, H. Sengeløv, 2018, Journal of Cancer Research and Clinical Oncology.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

M. Zwahlen, A. Mocroft, M. Egger, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

C. Leen, A. Mocroft, O. Kirk, 2017, HIV medicine.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

J. Nielsen, C. Leen, P. Vanhems, 2015, HIV medicine.

Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe

A. Mocroft, O. Kirk, J. van Lunzen, 2014, PloS one.

Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study

A. Mocroft, O. Kirk, J. Lazarus, 2012, BMC Infectious Diseases.

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

A. Mocroft, O. Kirk, H. Furrer, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study

A. Mocroft, M. Egger, J. Lundgren, 2009, Antiviral therapy.

The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.

A. Mocroft, O. Kirk, J. Lundgren, 2008, Central European journal of public health.

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.

A. Mocroft, B. Clotet, V. Soriano, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/µl in the era of cART

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2008, Scandinavian journal of infectious diseases.

Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.

A. Mocroft, A. Phillips, B. Ledergerber, 2006, The Journal of infectious diseases.

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.

A. Mocroft, C. Katlama, A. Phillips, 1997, International journal of epidemiology.

A. Mocroft, O. Kirk, J. Lundgren, 2015, AIDS.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA

C. Leen, A. Mocroft, A. d’Arminio Monforte, 2019, HIV medicine.

Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study\.

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2020, Journal of acquired immune deficiency syndromes.

Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D A D Cohort Analysis

A. Mocroft, R. Weber, C. Sabin, 2018, Journal of acquired immune deficiency syndromes.

Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, Annals of Internal Medicine.

HIV Therapies and the Kidney: Some Good, Some Not So Good?

A. Mocroft, J. Lundgren, L. Ryom, 2012, Current HIV/AIDS Reports.

Does European or non‐European origin influence health care and prognosis for HIV patients in Europe?

A. Mocroft, A. Blaxhult, J. Lundgren, 1999, HIV Medicine.

Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

A. Mocroft, O. Kirk, N. Chentsova, 2011, AIDS.

Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

A. Mocroft, O. Kirk, J. Lundgren, 2015, HIV medicine.

Clinical outcomes in clinical trials of anti-HIV treatment

A. Mocroft, J. Lundgren, J. Neaton, 2007 .

Healthcare delivery for HIV‐positive people with tuberculosis in Europe

A. Mocroft, O. Kirk, M. Inglot, 2020, HIV medicine.

Starting highly active antiretroviral therapy: why, when and response to HAART.

A. Mocroft, J. Lundgren, 2004, The Journal of antimicrobial chemotherapy.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

A. Mocroft, O. Kirk, P. Reiss, 2016, The lancet. HIV.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression

A. Mocroft, R. Paredes, H. Stellbrink, 2016, Medicine.

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

A. Mocroft, O. Kirk, A. Phillips, 2014, Infection.

Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.

A. Mocroft, F. Antunes, V. Soriano, 2010, The Journal of antimicrobial chemotherapy.

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Journal of acquired immune deficiency syndromes.

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

A. Mocroft, J. Montaner, C. Sabin, 2009, AIDS.

Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

A. Mocroft, F. Antunes, A. d’Arminio Monforte, 2008, HIV medicine.

Associations between serum albumin and serious non-AIDS events among people living with HIV

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, AIDS.

Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the Copenhagen Comorbidity in HIV Infection (COCOMO) study*

A. Mocroft, J. Lundgren, P. Oturai, 2019, HIV medicine.

Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

A. Mocroft, O. Kirk, J. González, 2021, BMC Infectious Diseases.

Higher rates of triple‐class virological failure in perinatally HIV‐infected teenagers compared with heterosexually infected young adults in Europe

A. Mocroft, D. Podzamczer, C. Sabin, 2016, HIV medicine.

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.

A. Mocroft, O. Kirk, H. Furrer, 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy (vol 162, pg 865, 2000)

A. Mocroft, R. Brettle, O. Kirk, 2003 .

Higher risk of abdominal obesity , elevated LDL cholesterol and hypertriglyceridemia , but not of hypertension , in people living with HIV : results from the Copenhagen Comorbidity in HIV infection ( COCOMO ) Study

A. Mocroft, B. Nordestgaard, K. Kofoed, 2018 .

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

A. Mocroft, C. Sabin, M. Battegay, 2015, AIDS.

Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the COCOMO study

A. Mocroft, J. Lundgren, P. Oturai, 2019 .

Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus.

A. Mocroft, J. Vestbo, J. Reekie, 2020, The Journal of infectious diseases.

Contemporary protease inhibitors and cardiovascular risk

A. Mocroft, J. Lundgren, L. Ryom, 2018, Current opinion in infectious diseases.

Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations

A. Mocroft, O. Kirk, J. Lundgren, 2018, AIDS.

Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America

A. Mocroft, O. Kirk, A. Schultze, 2014, Journal of the International AIDS Society.

Abdominal adipose tissue is associated with alterations in tryptophan-kynurenine metabolism and markers of systemic inflammation in people with HIV.

H. Ullum, A. Mocroft, J. Lundgren, 2019, The Journal of infectious diseases.

Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure

A. Mocroft, J. Lundgren, K. Kofoed, 2019, BMC Infectious Diseases.

Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort

C. Leen, A. Mocroft, R. Weber, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort

A. Mocroft, O. Kirk, F. Antunes, 2005, AIDS.

Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection

A. Mocroft, H. Günthard, E. Bernasconi, 2022, Frontiers in Medicine.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?

A. Mocroft, O. Kirk, C. Katlama, 2005, Antiviral therapy.

Increased incidence rates of positive blood cultures shortly after chemotherapy compared to radiotherapy among individuals treated for solid malignant tumours

A. Mocroft, J. Lundgren, L. Specht, 2022, Infection.

Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

A. Mocroft, O. Kirk, D. Raben, 2021, HIV research & clinical practice.

Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

A. Mocroft, O. Kirk, A. Blaxhult, 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2016, HIV medicine.

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral therapy.

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

A. Mocroft, O. Kirk, M. Johnson, 2015, PLoS medicine.

The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences

A. Mocroft, J. Lazarus, J. Lundgren, 2021, AIDS.

A comparison of the long‐term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

A. Mocroft, J. Lundgren, C. Katlama, 2011, HIV medicine.

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, The lancet. HIV.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.

The cardiovascular risk management for people living with HIV in Europe: how well are we doing?

A. Mocroft, O. Kirk, A. Schultze, 2016, AIDS.

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

A. Mocroft, J. Lundgren, M. Laguno, 2020, Open forum infectious diseases.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

A. Mocroft, H. Günthard, D. Podzamczer, 2013, The Journal of infectious diseases.

Erratum: Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4 + T-cell counts (Antiviral Therapy (2007) 12, (325-333))

A. Mocroft, R. Weber, A. Phillips, 2007 .

Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected Patients with High and Low CD4+ T-Cell Counts

A. Mocroft, R. Weber, J. Gatell, 2007, Antiviral therapy.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Andrew Phillips, Esteban Martínez, Xavier Carné, 2001, AIDS.

Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis

A. Mocroft, O. Kirk, J. Lundgren, 2014, AIDS.

Reference curves for CD4 T‐cell count response to combination antiretroviral therapy in HIV‐1‐infected treatment‐naïve patients

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2017, HIV medicine.

Reference curves for CD 4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na € ı ve patients

A. Mocroft, C. Sabin, M. Battegay, 2016 .

Anemia and survival in human immunodeficiency virus.

A. Mocroft, J. Lundgren, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors.

A. Mocroft, O. Kirk, P. Reiss, 2013, The Journal of infection.

Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries

J. Sterne, A. Mocroft, M. Egger, 2015 .

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, The lancet. HIV.

Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV

A. Mocroft, P. Reiss, J. Reekie, 2022, AIDS.

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina Reekie,

A. Mocroft, O. Kirk, J. Lundgren, 2018 .

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

A. Levey, A. Mocroft, L. Inker, 2020, Kidney international reports.

The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people

A. Mocroft, J. Lundgren, J. Weber, 2018, HIV medicine.

Tenofovir disoproxil fumarate withdrawal and cardiovascular risk – Authors' reply

A. Mocroft, L. Ryom, L. Peters, 2023, The Lancet HIV.

Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons

A. Mocroft, J. Lundgren, L. Ryom, 2014, Current opinion in HIV and AIDS.

A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study

A. Mocroft, O. Kirk, B. Ledergerber, 2011, HIV clinical trials.

Erratum: A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study (Journal of Infectious Disease (2002) 185 (178-187))

A. Mocroft, J. Lundgren, G. Jm, 2002 .

The benefits and risks of PrEP and kidney function.

A. Mocroft, L. Ryom, 2016, The lancet. HIV.

Classification of death causes after transplantation (CLASS)

A. Mocroft, J. Lundgren, H. Sengeløv, 2017, Medicine.

Classi fi cation of death causes after transplantation ( CLASS ) Evaluation of methodology and initial results

A. Mocroft, J. Lundgren, H. Sengeløv, 2018 .

Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study

A. Mocroft, B. Clotet, V. Soriano, 2011, Antiviral therapy.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

A. Mocroft, C. Katlama, P. Reiss, 2015, The lancet. HIV.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Peter Reiss, Ole Kirk, Eric Fontas, 2018, The lancet. HIV.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, The Lancet.

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

A. Mocroft, O. Kirk, J. Lundgren, 2003, The Lancet.

Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

A. Mocroft, O. Kirk, C. Tural, 2005, The Journal of infectious diseases.

Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey

A. Mocroft, J. Lazarus, M. Johnson, 2016, BMC Infectious Diseases.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, The Lancet.

A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

A. Mocroft, O. Kirk, A. Blaxhult, 2002, The Journal of infectious diseases.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2016, International journal of epidemiology.

No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

M. Zwahlen, A. Mocroft, O. Kirk, 2021, Journal of the International AIDS Society.

Cervical cancer risk in women living with HIV across four continents: A multicohort study

Richard D Moore, J. Goedert, S. Franceschi, 2020, International journal of cancer.

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2014, International journal of epidemiology.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

A. Mocroft, D. Podzamczer, A. Phillips, 2012, The Lancet. Infectious diseases.

Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe

A. Mocroft, D. Podzamczer, A. Phillips, 2011, Journal of acquired immune deficiency syndromes.

The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology

J. Sterne, A. Mocroft, O. Kirk, 2011, Epidemiology.

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

A. Mocroft, M. Egger, J. Lundgren, 2009, AIDS.

Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral Therapy.

Staging system for clinical AIDS patients

A. Mocroft, C. Sabin, M. Youle, 1995, The Lancet.

Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994–2001

EuroSIDA, A. Mocroft, O. Kirk, 2004, European Journal of Clinical Microbiology and Infectious Diseases.

Increased incidence rates of positive blood cultures shortly after chemotherapy compared to radiotherapy among individuals treated for solid malignant tumours

A. Mocroft, J. Lundgren, L. Specht, 2022, Infection.

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

A. Mocroft, C. Sabin, A. Phillips, 1999, Journal of acquired immune deficiency syndromes.

Regional differences in presentation of AIDS in Europe

A. Mocroft, O. Kirk, A. Blaxhult, 2000, Epidemiology and Infection.

Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation

A. Mocroft, J. Lundgren, H. Sengeløv, 2018, Transplantation direct.

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation

A. Mocroft, J. Lundgren, H. Sengeløv, 2018, Open forum infectious diseases.

[Decline in AIDS and death rates in the EuroSIDA study. An observational study].

A. Mocroft, O. Kirk, J. Lundgren, 2004, Ugeskrift for laeger.

Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption

A. Mocroft, B. Clotet, J. Lundgren, 2010, AIDS.

Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?

A. Mocroft, O. Kirk, B. Clotet, 2005, AIDS.

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.

Ross J. Harris, J. Sterne, A. Mocroft, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

A. Mocroft, O. Kirk, V. Soriano, 2013, Journal of hepatology.

Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients

A. Mocroft, O. Kirk, V. Soriano, 2012, AIDS.

Changing patterns of mortality across Europe in patients infected with HIV-1

JD Lundgren, A Mocroft, A. Mocroft, 1998, The Lancet.

The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

A. Mocroft, J. Miro, M. Cavassini, 2021, HIV medicine.

Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

A. Mocroft, O. Kirk, V. Soriano, 2006, Scandinavian journal of infectious diseases.

Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study

A. Mocroft, J. Lundgren, J. Rockstroh, 2018, Antiviral therapy.

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study

A. Mocroft, O. Kirk, B. Clotet, 2008, AIDS.

The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study

A. Mocroft, A. Blaxhult, S. Staszewski, 2008, AIDS.

Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe

A. Mocroft, O. Kirk, J. Gatell, 2006, Journal of acquired immune deficiency syndromes.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.

A. Mocroft, O. Kirk, A. Blaxhult, 2005, AIDS research and human retroviruses.

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

A. Mocroft, O. Kirk, J. Gatell, 2010, AIDS.

Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression

A. Mocroft, V. Soriano, P. Reiss, 2009, Journal of acquired immune deficiency syndromes.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

AIDS across Europe, 1994–98: the EuroSIDA study

A. Mocroft, O. Kirk, F. Antunes, 2000, The Lancet.

A. Mocroft, O. Kirk, A. Blaxhult, 2005, AIDS research and human retroviruses.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA*

A. Mocroft, O. Kirk, J. Lundgren, 2013, HIV medicine.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

Soriano, A. Mocroft, O. Kirk, 2012 .

Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study

A. Mocroft, P. Reiss, J. Lundgren, 2009, Antiviral therapy.

Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections

A. Mocroft, J. Lundgren, H. Sengeløv, 2015, EBioMedicine.

Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.

A. Mocroft, P. Griffiths, V. Emery, 1999, AIDS.

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

A. Mocroft, O. Kirk, J. Gatell, 2010, Journal of acquired immune deficiency syndromes.

Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?

A. Mocroft, A. Phillips, M. Gill, 2000, Journal of acquired immune deficiency syndromes.

The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003

A. Mocroft, O. Kirk, F. Antunes, 2004, Cancer.

Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

A. Mocroft, O. Kirk, M. Dietrich, 1999, AIDS.

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection

A. Mocroft, O. Kirk, A. Phillips, 1999, The Lancet.

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

A. Mocroft, O. Kirk, A. Schultze, 2018, BMC Infectious Diseases.

The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression

A. Mocroft, O. Kirk, J. Gatell, 2012, Antiviral therapy.

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV

A. Mocroft, D. Wentworth, B. Angus, 2010, AIDS.

Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study

A. Mocroft, F. Antunes, J. van Lunzen, 1999, Annals of Internal Medicine.

TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

A. Mocroft, O. Kirk, H. Furrer, 2013, BioMed research international.

Biomarkers of impaired renal function

A. Mocroft, F. Post, C. Wyatt, 2010, Current opinion in HIV and AIDS.

Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy

A. Mocroft, O. Kirk, A. Phillips, 2010, Antiviral therapy.

The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era

A. Mocroft, F. Antunes, A. Phillips, 2006, Clinical trials.

Regional survival differences across Europe in HIV-positive people: the EuroSIDA study.

A. Mocroft, J. Lundgren, C. Katlama, 1999, AIDS.

Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study

A. Mocroft, B. Clotet, L. Ruiz, 2008, Journal of acquired immune deficiency syndromes.

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements

Ross J. Harris, J. Sterne, A. Mocroft, 2009, AIDS.

Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor

A. Mocroft, A. Phillips, M. Gill, 1998, AIDS.

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.

A. Mocroft, O. Kirk, B. Clotet, 2002, The Journal of infectious diseases.

Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population

A. Mocroft, L. Madsen, J. Hansen, 2022, Journal of hepatocellular carcinoma.

Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.

A. Mocroft, J. Lundgren, A. Horban, 2004, The Journal of infectious diseases.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

A. Mocroft, O. Kirk, A. Blaxhult, 2007, HIV medicine.

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

Ignacio Conget, Andrew Phillips, Esteban Martínez, 2001, The Lancet.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

A. Mocroft, O. Kirk, F. Antunes, 2000, Archives of internal medicine.

Changes in hospital admissions across Europe: 1995–2003. Results from the EuroSIDA study

A. Mocroft, O. Kirk, A. Blaxhult, 2004, HIV medicine.

Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies

A. Mocroft, O. Kirk, F. Antunes, 2010, Cancer.

Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps

A. Mocroft, O. Kirk, J. Lundgren, 2021, HIV medicine.

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study☆

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, EClinicalMedicine.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

A. Mocroft, O. Kirk, B. Clotet, 2008, AIDS.

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2001 .

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort

A. Mocroft, B. Clotet, J. Lundgren, 2018, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

A. Mocroft, A. Phillips, S. Staszewski, 2004, The Journal of infectious diseases.

The Incidence of AIDS-De fi ning Illnesses at a Current CD 4 Count ≥ 200 Cells / μ L in the Post – Combination Antiretroviral Therapy Era

B. Gazzard, A. Mocroft, O. Kirk, 2013 .

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

A. Mocroft, P. Francioli, J. Gatell, 2011, AIDS.

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

A. Mocroft, O. Kirk, J. Lundgren, 2014, BMC Infectious Diseases.

Castagna, A. Mocroft, O. Kirk, 2016, HIV medicine.

Stability of hepatitis C virus (HCV) RNA levels among interferon‐naïve HIV/HCV‐coinfected individuals treated with combination antiretroviral therapy

A. Mocroft, O. Kirk, B. Ledergerber, 2013, HIV medicine.

Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4+ T-cell Counts

A. Mocroft, R. Weber, A. Phillips, 2006, Antiviral Therapy.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study

A. Mocroft, R. Weber, C. Sabin, 2017, PLoS medicine.

Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey

A. Mocroft, O. Kirk, C. Katlama, 2010, Journal of acquired immune deficiency syndromes.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, AIDS.

HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe

A. Mocroft, H. Stellbrink, J. Lundgren, 2021, HIV medicine.

The EuroSIDA study: 25 years of scientific achievements

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, HIV medicine.

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals

C. Leen, A. Mocroft, J. Gatell, 2018, AIDS.

High rate of hepatitis C virus (HCV) recurrence in HIV‐infected individuals with spontaneous HCV RNA clearance

A. Mocroft, J. Lundgren, C. Katlama, 2014, HIV medicine.

Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

Anders Karlsson, Jens D. Lundgren, Christian Pradier, 2013, PloS one.

Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012 .

Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)

Stefan Esser, Josip Begovac, Jens D. Lundgren, 2013, PloS one.

Airflow limitation in people living with HIV and matched uninfected controls

A. Mocroft, B. Nordestgaard, J. Vestbo, 2018, Thorax.

Hepatitis C virus (HCV) RNA profiles among chronic HIV/HCV‐coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in nine individuals

A. Mocroft, J. Rockstroh, C. Boesecke, 2017, HIV medicine.

HCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals

A. Mocroft, J. Rockstroh, C. Boesecke, 2016 .

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

C. Leen, A. Mocroft, J. Lundgren, 2021, JAIDS Journal of Acquired Immune Deficiency Syndromes.

Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study.

C. Leen, A. Mocroft, J. Lundgren, 2020, Journal of acquired immune deficiency syndromes.

Prevalence and outcomes of pregnancies in women living with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015.

A. Mocroft, M. Battegay, D. Raben, 2021, AIDS.

Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors

A. Mocroft, B. Nordestgaard, L. Køber, 2019, AIDS.

Chronic renal failure among HIV-1-infected patients

A. Mocroft, O. Kirk, J. Gatell, 2007, AIDS.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

A. Mocroft, C. Sabin, M. Battegay, 2017, Journal of the National Cancer Institute.

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.

L. Myer, A. Mocroft, M. Egger, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe.

A. Mocroft, J. Lundgren, V. Vullo, 2019, AIDS.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C

L. Kuller, A. Mocroft, W. El-Sadr, 2009, AIDS.

Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study

A. Mocroft, O. Kirk, J. Lundgren, 2012, PLoS ONE.

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

A. Mocroft, O. Kirk, J. Lundgren, 2010, AIDS.

Development and validation of a cycle‐specific risk score for febrile neutropenia during chemotherapy cycles 2–6 in patients with solid cancers: The CSRFENCE score

A. Mocroft, J. Lundgren, L. Specht, 2020, International journal of cancer.

Development and validation of a cycle-speci ﬁ c risk score for febrile neutropenia during chemotherapy cycles 2 – 6 in patients with solid cancers: The CSR FENCE score

A. Mocroft, J. Lundgren, J. Reekie, 2019 .

Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score

A. Mocroft, J. Lundgren, L. Specht, 2018, JNCI cancer spectrum.

“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”

A. Mocroft, J. Lundgren, H. Sengeløv, 2019, Journal of Cancer Research and Clinical Oncology.

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

A. Mocroft, O. Kirk, A. Schultze, 2018, The Journal of infection.

A. Mocroft, O. Kirk, A. Schultze, 2016, The lancet. HIV.

Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America

A. Mocroft, O. Kirk, A. Schultze, 2015, PLoS ONE.

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients

Mark P Khurana, A. Mocroft, J. Lundgren, 2018, Open forum infectious diseases.

Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results

A. Mocroft, J. Lundgren, H. Sengeløv, 2017 .

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

A. Mocroft, A. d’Arminio Monforte, A. Clarke, 2018, HIV medicine.

Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons.

C. Leen, A. Mocroft, O. Kirk, 2014, The Journal of infectious diseases.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Anne M Johnson, A. Mocroft, O. Kirk, 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study

A. Grzeszczuk, M. L. Jakobsen, J. Minton, 2015, PloS one.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Peter Reiss, Ole Kirk, Lene Ryom, 2013, The Journal of infectious diseases.

Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score

A. Mocroft, O. Kirk, P. Francioli, 2007, AIDS.

Impact of Age and HIV Status on Immune Activation, Senescence and Apoptosis

H. Ullum, A. Mocroft, B. Nordestgaard, 2020, Frontiers in Immunology.

Prevalence and Risk Factors of Moderate to Severe Hepatic Steatosis in HIV Infection: The Copenhagen Co-Morbidity Liver Study.

A. Mocroft, B. Nordestgaard, L. Køber, 2020, The Journal of infectious diseases.

Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study

A. Mocroft, B. Nordestgaard, J. Lundgren, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

A. Mocroft, J. Lundgren, L. Specht, 2020, Cancer medicine.

Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls

A. Mocroft, B. Nordestgaard, J. Vestbo, 2018, HIV medicine.

Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study

A. Mocroft, J. Lundgren, B. Clotet, 2002, Antiviral therapy.

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

A. Mocroft, J. Parkin, R. Weber, 2001, AIDS.

Changing incidence of central nervous system diseases in the EuroSIDA cohort

A. Mocroft, O. Kirk, F. Antunes, 2004, Annals of neurology.

MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year

A. Mocroft, J. Lundgren, A. Rasmussen, 2016, Scandinavian Journal of Gastroenterology.

Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls

A. Mocroft, B. Nordestgaard, L. Køber, 2022 .

External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.

A. Mocroft, H. Günthard, J. Rockstroh, 2023, Journal of hepatology.

Thrombocytopenia and cancer risk during HIV infection.

A. Mocroft, J. Lundgren, Á. Borges, 2015, AIDS.

Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease

A. Mocroft, A. Blaxhult, F. Antunes, 2014, AIDS (London).

Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

A. Mocroft, J. Reekie, M. Cavassini, 2022, AIDS.

Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, AIDS.

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

A. Mocroft, J. Gallant, F. Wit, 2022, HIV medicine.

Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.

A. Mocroft, R. Brettle, O. Kirk, 2000, American journal of respiratory and critical care medicine.

Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection.

A. Mocroft, A. Blaxhult, J. van Lunzen, 2007, AIDS research and human retroviruses.

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

A. Mocroft, R. Hogg, C. Sabin, 2014, CMAJ open.

The relationship between smoking, current CD4, viral load and cancer in persons living with HIV.

A. Mocroft, 2020, AIDS.

HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe

A. Mocroft, L. Ruiz, A. Phillips, 2006, Antiviral therapy.

A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2013, HIV Medicine.

History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change *

A. Mocroft, J. Lundgren, B. Clotet, 2010, HIV medicine.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

B. Gazzard, A. Mocroft, O. Kirk, 2008, AIDS.

Virological Failure among Patients on Haart from across Europe: Results from the Eurosida Study

B Clotet, A Mocroft, A Blaxhult, 1999, Antiviral therapy.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Anne M Johnson, Jens D. Lundgren, Anders Blaxhult, 1999, Journal of acquired immune deficiency syndromes.

Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy

A. Mocroft, O. Kirk, A. Blaxhult, 2004, AIDS.

The difficulties of classifying renal disease in HIV‐infected patients *

A. Mocroft, 2011, HIV medicine.

A clinically useful risk-score for chronic kidney disease in HIV infection

A. Mocroft, O. Kirk, M. Johnson, 2014, Journal of the International AIDS Society.

Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Mark P Khurana, A. Mocroft, J. Lundgren, 2019, Open forum infectious diseases.

Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

A. Mocroft, O. Kirk, C. Sabin, 2016, The Journal of infectious diseases.

Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

A. Mocroft, H. Furrer, J. Neuhaus, 2015, HIV medicine.

Hepatitis B (HBV) and Hepatitis C (HCV) in the EuroSIDA Cohort: Prevalence and Impact on Mortality, Aids Progression and Response to HAART.

A. Mocroft, O. Kirk, F. Antunes, 2004 .

All-cause mortality in treated HIV-infected adults with CD4 5500/mm compared with the general population: evidence from a large European observational cohort collaborationy

A. Mocroft, O. Kirk, M. Egger, 2022 .

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

M. Zwahlen, A. Mocroft, O. Kirk, 2020, Clinical Infectious Diseases.

Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE.

J. Carpenter, M. Zwahlen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

A. Mocroft, H. Furrer, A. Clarke, 2017, International journal of antimicrobial agents.

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2021, Journal of the International AIDS Society.

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments

A. Mocroft, C. Wyatt, Melinda M. Nugent, 2016, Current HIV/AIDS Reports.

Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition

A. Mocroft, 2014, HIV medicine.

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2014, Journal of the International AIDS Society.

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

A. Mocroft, J. Gatell, P. Reiss, 2017, AIDS.

Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study.

A. Mocroft, J. Lundgren, D. Duprez, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression

A. Mocroft, R. Paredes, C. Pedersen, 2014, Journal of the International AIDS Society.

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of Infectious Diseases.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study

A. Mocroft, O. Kirk, C. Sabin, 2014, BMC Nephrology.

Use of contemporary protease inhibitors and risk of incident chronic kidney disease in HIV-positive persons; the D:A:D Study.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of infectious diseases.

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis

J. Sterne, A. Mocroft, P. Reiss, 2016, AIDS.

Hepatitis delta infection among persons living with HIV in Europe

A. Mocroft, H. Günthard, J. Rockstroh, 2023, Liver international : official journal of the International Association for the Study of the Liver.

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2004 .

Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV‐1‐infected patients treated with abacavir

A. Mocroft, O. Kirk, J. Lundgren, 2010, HIV medicine.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015

B. Gazzard, A. Mocroft, A. d’Arminio Monforte, 2019, PloS one.

Regional differences in self-reported HIV care and management in the EuroSIDA study

A. Mocroft, O. Kirk, J. Lazarus, 2014, Journal of the International AIDS Society.

Loss to follow‐up in an international, multicentre observational study

JD Lundgren, A Mocroft, O Kirk, 2008, HIV medicine.

Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

A. Mocroft, O. Kirk, H. Furrer, 2013, European Respiratory Journal.

Serious clinical events in HIV-positive persons with chronic kidney disease (CKD).

A. Mocroft, O. Kirk, R. Weber, 2019, AIDS.

Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV

P. Vanhems, A. Mocroft, A. Phillips, 2005, The American Journal of Gastroenterology.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

J. Sterne, A. Sabin, A. Mocroft, 2018, HIV medicine.

Changes in use of antiretroviral therapy in regions of Europe over time

A. Mocroft, R. Brettle, O. Kirk, 1998, AIDS.

Associations between HIV-RNA-based indicators and virological and clinical outcomes

A. Mocroft, O. Kirk, J. Lundgren, 2016, AIDS.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Participation in clinical studies among patients infected with HIV‐1 in a single treatment centre over 12 years

A. Mocroft, A. Phillips, M. Youle, 2000, HIV medicine.

Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV.

R. Haubrich, C. Leen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV.

A. Mocroft, B. Nordestgaard, L. Køber, 2019, AIDS (London).

Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study

A. Mocroft, M. van der Valk, K. Kusejko, 2022, Open forum infectious diseases.

Deterioration of Renal Function Associated with Current Level of Immunodeficiency

A. Mocroft, O. Kirk, P. Reiss, 2008 .

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct‐acting antivirals—Results from the EuroSIDA study

C. Leen, A. Mocroft, A. Winston, 2022, HIV medicine.

Antiviral therapy

A. Mocroft, C. Sabin, A. Phillips, 1995, Nature.

Impact of antiretroviral therapy (ART), immunosuppression and viraemia on lipid levels: the D:A:D study

A. Mocroft, J. Lundgren, C. Sabin, 2012 .

O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) – myocardial infarction and abacavir use

A. Mocroft, O. Kirk, J. Lundgren, 2008 .

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2023, Cancers.

CD4 count and viral load specific rates of AIDS, non‐AIDS and deaths according to current antiretroviral use

A. Mocroft, O. Kirk, A. Phillips, 2012, AIDS.

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

A. Mocroft, O. Kirk, H. Furrer, 2001, The New England journal of medicine.

One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America

A. Mocroft, O. Kirk, H. Furrer, 2017, AIDS.

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

JD Lundgren, N Clumeck, A. Mocroft, 2007, The Lancet.

The effectiveness of indicator disease-based HIV testing across Europe - results from a prospective multi-centre study

M. Jakobsen, B. Gazzard, A. Mocroft, 2015 .

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0

S. McCormack, A. Mocroft, O. Kirk, 2018, HIV medicine.

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

A. Mocroft, S. Gange, C. Sabin, 2010, The Lancet.

Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV‐1‐infected patients treated with abacavir

A. Mocroft, O. Kirk, P. Reiss, 2010, HIV Medicine.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.